Literature DB >> 9740780

Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

N P Restifo1, D R Surman, H Zheng, P Palese, S A Rosenberg, A García-Sastre.   

Abstract

Using reverse genetics methods, we constructed three different transfectant influenza A viruses encoding an Ld-restricted, nine amino-acid-long fragment, corresponding to amino-acid residues 876-884, of beta-galactosidase (beta-gal). Sequences encoding this epitope were nested within the hemagglutinin (HA) or neuraminidase (NA) open reading frames. Alternatively, an independent beta-gal mini-gene, preceded by an endoplasmic reticulum insertion signal sequence, was placed in a bicistronic arrangement in the NA RNA segment of the virus. All three transfectants mediated the presentation of the epitope to a beta-gal-specific CTL clone. Furthermore, each of the three transfectant viruses expressing the beta-gal fragment elicited specific cytolytic responses in vivo. Most importantly, these H1N1 transfectants mediated the regression of established murine pulmonary metastases. Tumor regression in mice was also achieved in the presence of preexisting immunity against an H3N2 influenza A virus serotype. Nononcogenic and nonintegrating, transfectant influenza A viruses are attractive candidates for development as antitumor vaccines. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740780      PMCID: PMC2556857          DOI: 10.1006/viro.1998.9330

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

2.  An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice.

Authors:  T Muster; E K Subbarao; M Enami; B R Murphy; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

Review 3.  Genetic manipulation of negative-strand RNA virus genomes.

Authors:  A García-Sastre; P Palese
Journal:  Annu Rev Microbiol       Date:  1993       Impact factor: 15.500

4.  Engineering poliovirus as a vaccine vector for the expression of diverse antigens.

Authors:  R Andino; D Silvera; S D Suggett; P L Achacoso; C J Miller; D Baltimore; M B Feinberg
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

Review 5.  Use of temperature-sensitive and cold-adapted mutant viruses in immunoprophylaxis of acute respiratory tract disease.

Authors:  R M Chanock; B R Murphy
Journal:  Rev Infect Dis       Date:  1980 May-Jun

6.  Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus.

Authors:  A García-Sastre; T Muster; W S Barclay; N Percy; P Palese
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Authors:  K R Irvine; R S Chamberlain; E P Shulman; D R Surman; S A Rosenberg; N P Restifo
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

Review 8.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

9.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes.

Authors:  M A Gavin; M J Gilbert; S R Riddell; P D Greenberg; M J Bevan
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

View more
  13 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency.

Authors:  Markus Wolschek; Elisabeth Samm; Helena Seper; Sanda Sturlan; Irina Kuznetsova; Cornelia Schwager; Alexandra Khassidov; Christian Kittel; Thomas Muster; Andrej Egorov; Michael Bergmann
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

3.  Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Authors:  Tokiko Watanabe; Shinji Watanabe; Gabriele Neumann; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Authors:  W W Overwijk; M R Theoret; N P Restifo
Journal:  Cancer J Sci Am       Date:  2000-02

5.  Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.

Authors:  A McAllister; A E Arbetman; S Mandl; C Peña-Rossi; R Andino
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice.

Authors:  B Ferko; J Stasakova; S Sereinig; J Romanova; D Katinger; B Niebler; H Katinger; A Egorov
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses.

Authors:  C F Basler; A García-Sastre; P Palese
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.

Authors:  Tokiko Watanabe; Shinji Watanabe; Takeshi Noda; Yutaka Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.

Authors:  Seunghee Kim-Schulze; Hong Sung Kim; Qing Fan; Dae Won Kim; Howard L Kaufman
Journal:  Mol Ther       Date:  2008-11-25       Impact factor: 11.454

10.  Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.

Authors:  Clay L Efferson; Jeanne Schickli; Byung Kyum Ko; Kouichiro Kawano; Sara Mouzi; Peter Palese; Adolfo García-Sastre; Constantin G Ioannides
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.